

## **Three Year Follow up of GMCSF/bi-shRNA<sup>furin</sup> DNA Transfected Autologous Tumor Immunotherapy (Vigil™) in Metastatic Advanced Ewing's Sarcoma**

Maurizio Ghisoli<sup>1,2,4</sup>, Minal Barve<sup>1,2</sup>, Robert Mennel<sup>2,5</sup>, Carl Lenarsky<sup>2,4</sup>, Staci Horvath<sup>1</sup>, Gladice Wallraven<sup>3</sup>, Beena O Pappen<sup>3</sup>, Sam Whiting<sup>3</sup>, Donald Rao<sup>6</sup>, Neil Senzer<sup>1,3</sup>, John Nemunaitis<sup>1,2,3,4,6</sup>

<sup>1</sup>Mary Crowley Cancer Research Centers, Dallas, TX; <sup>2</sup>Texas Oncology, P.A., Dallas, TX  
<sup>3</sup>Gradalis, Inc., Dallas, TX; <sup>4</sup>Medical City Dallas Hospital, Dallas, TX; <sup>5</sup>Baylor University Medical Center, Dallas, TX; <sup>6</sup>Strike Bio, Dallas, TX

### **Address All Reprint Requests To:**

John Nemunaitis, M.D.  
12222 Merit Drive  
Suite 1500  
Dallas, Texas 75251  
Phone: 214-658-1964  
Fax: 214-658-1992  
E-mail: [jnemunaitis@marycrowley.org](mailto:jnemunaitis@marycrowley.org)

**ABSTRACT**

Ewing's sarcoma is a devastating rare pediatric cancer of the bone. Intense chemotherapy temporarily controls disease in most patients at presentation but has limited effect in patients with progressive or recurrent disease. We previously described preliminary results of a novel immunotherapy, FANG<sup>TM</sup> (Vigil<sup>TM</sup>) vaccine, in which 12 advanced stage Ewing's patients were safely treated and went on to achieve a predicted immune response (IFN $\gamma$  ELISPOT). We describe follow-up through year 3 of a prospective, non-randomized study comparing an expanded group of Vigil-treated advanced disease Ewing's sarcoma patients (n=16) with a contemporaneous group of Ewing's sarcoma patients (n=14) not treated with Vigil. Long-term follow up results show a survival benefit without evidence of significant toxicity (no  $\geq$  grade 3) to Vigil when administered once monthly by intradermal injection ( $1 \times 10^6$  cells/injection to  $1 \times 10^7$  cells/injection). Specifically, we report a 1-year actual survival of 73% for Vigil treated patients compared to 23% in those not treated with Vigil. In addition, there was a 17.2 month difference in overall survival (OS; Kaplan-Meier) between the Vigil (median OS 731 days) and no Vigil patient groups (median OS 207 days). In conclusion, these results supply the rationale for further testing of Vigil in advanced stage Ewing's sarcoma.

## INTRODUCTION

Ewing's sarcoma is a malignant cancer of the bones with rapid spread to the lungs. It is the second most frequently diagnosed primary malignant bone tumor in the USA with annual incidence of 1 in a million [1, 2]. *Approximately 20-30% of Ewing's sarcoma cases are diagnosed in the first decade and 10% after age 20. The median age of diagnosis is 14 -15 years old [3, 4].*

Although less than 25% of patients present with overt metastatic disease, based on relapse patterns subclinical metastases are presumably present in up to 80% of children at diagnosis[4-8]. The median time to relapse in unselected populations is 1.3 years [4, 8]. Patients who relapse have a marked reduction in 1-year and 5-year survival.

Few recurrent patients respond to second-line therapy and even fewer achieve a second remission [4, 8-13], particularly in those who relapse within 2 years of front-line treatment. In one large retrospective analysis of 714 patients from time of first relapse, the 1-year overall survival (OS) was 43%, 5-year OS was 13%, and 10-year OS was 9% [4]. At time of first relapse, the most significant prognostic factors are time to relapse (<2 vs. ≥2 years) and site[s] of recurrence (localized, metastatic, or combined localized and metastatic). For relapses that occur within the first 2 years after initial diagnosis, which make up 72% of relapses [4], the 2-year OS from relapse is 7% [10]. In 2 other analyses 5-year PFS (progression-free survival) was 5% [13] and 5-year OS 7% [4].

Regarding the significance effect of metastatic disease as an independent factor related to response [14], in one assessment, metastatic disease at presentation in 24 patients (13 with lung metastases, 12 with distant bone metastases, and 1 with bone marrow involvement) the 5-year OS from presentation with metastatic disease was 27% versus 85% for patients with localized disease (n=77,  $P < 0.0001$ ) and the 5-year PFS was 28% versus 73% ( $P < 0.001$ ).

Second-line chemotherapy for relapsed Ewing's sarcoma generally shows limited efficacy with only 9% to 13% of patients achieving a second disease free remission [11, 13, 15]. Notably, the NCCN guidelines do not provide standard of care recommendations for second-line treatment. Regimens such as topotecan/cyclophosphamide, irinotecan/temozolomide, or docetaxel/gemcitabine have been utilized in second-line or later treatments and may prolong life for those who respond [16-29]. However, none of these regimens have been determined to have a significant advantage in randomized clinical assessments [30]. The irinotecan/temozolomide regimen appears to be the most common second-line regimen utilized today.

Third-line treatment for Ewing's sarcoma is associated with cumulative toxicity (hematologic and neurologic) in addition to an even lower response rate. There is no standard of care treatment for Ewing's sarcoma in the third-line or greater setting.

Previously [31], we reported preliminary results of 12 patients with advanced disease (multiply recurrent or treatment failure within 2 years) Ewing's sarcoma treated with Vigil™ (formerly known as FANG™) immunotherapy. Safety and immune responses were characterized and a preliminary 1-year survival of 75% was observed. We now report long-term follow-up of the

previously reported 12 and an additional four patients with advanced Ewing's sarcoma. We compared the results in these 16 patients to 14 contemporaneous patients with advanced Ewing's sarcoma who fulfilled the same inclusion criteria and underwent similar surgical procedure and vaccine construction but did not receive Vigil™.

Our observed preliminary results and now long-term follow-up of our expanded group of patients are a provocative observation in support of further randomized trial testing.

## **METHODS**

The construction and current good manufacturing practice (GMP) adherence of Vigil™ immunotherapy are summarized in Figure 1. Briefly, Vigil™ vector utilizes the pUMVC3 vector backbone in which the GMCSF encoding complementary DNA and the DNA encoding the furin bifunctional shRNA are under transcriptional control of the cytomegalovirus immediate-early promoter. The final construct was confirmed by bi-directional sequencing. Following protocol-specific informed consent, the tumor was excised, placed in sterile transport media, and brought to the Gradalis manufacturing facility (Carrollton, TX) for vaccine manufacture as previously described [32].

## **STUDY DESIGN**

Briefly, each patient entered into study received monthly doses of Vigil™ the concentrations of which were based on cell yield from procured tumor (1 x 10<sup>6</sup> cells / injection, 4.0 x 10<sup>6</sup> cells /

injection,  $8.3 \times 10^6$  cells / injection,  $1 \times 10^7$  cells/injection or  $2.5 \times 10^7$  cells/injection in 1 ml volume). A minimum of 4 doses to a maximum of 12 doses were administered via intradermal injection, alternating between the right and left upper arms. Patients were discontinued from study for progressive disease or intolerable toxicity. The trial was performed after approval by a local Ethics Committee and in accordance with an assurance filed with and approved by the Department of Health and Human Services.

## **PATIENT POPULATION**

The study population involved patients with Ewing's sarcoma (n=30) that was multiply recurrent or progressed within 2 years of treatment who, following study consent, underwent surgical tumor extraction and subsequent tumor processing for vaccine construction. These Ewing's sarcoma patients were a subset of the Phase 1 solid tumor study previously published [32]. Specific inclusion criteria included a histologically confirmed advanced or metastatic non-curable Ewing's sarcoma following completion of  $\geq 1$  disease appropriate standard of care therapy; recovery from all treatment-related toxicities to  $\leq$  Grade 1 (except alopecia); availability of tumor in sufficient quantity (a minimum of 2-8 grams of solid tumor tissue or at least 500 mL of pleural/ascites fluid) for vaccine processing; history of brain metastases allowed if treatment completed  $\geq 2$  months prior to enrollment with MRI confirmation of no active disease; presence of  $\geq 1$  measurable or evaluable lesion; patient age  $\geq 12$  years; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1; a signed, IRB approved, protocol-specific written informed consent document; a negative pregnancy test for women of child-bearing potential; and normal organ and marrow function defined as follows: absolute granulocyte count

(>1,500/mm<sup>3</sup>), platelets (>100,000/ mm<sup>3</sup>), total bilirubin (<2 mg/dL), AST(SGOT)/ALT(SGPT) (<2x institutional upper limit of normal), and creatinine (<1.5 mg/dL).

Exclusion criteria included: surgery involving general anesthesia, chemotherapy, radiotherapy, or immunotherapy within 4 weeks of study entry; use of other investigational agents within 30 days prior to study entry; known immune compromised state or autoimmune disease; prior malignancy (excluding non-melanoma skin cancer) unless in remission for  $\geq 2$  years; uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements; confirmation that patient was pregnant or nursing; HIV; or chronic hepatitis B or C infection [except in patients with hepatocellular carcinoma (HCC)].

All patients receiving vaccine (n=16) were treated in the outpatient facilities of Mary Crowley Cancer Research Centers (MCCRC), Dallas, TX. Twelve of the 16 patients treated with Vigil™ in this analysis were previously described [31] for early safety and response. Fourteen patients did not receive Vigil™ following procurement and vaccine manufacture (n=14) and were followed as a comparative, non-randomized but contemporarily alternatively treated group to the Vigil™ treated patients. Thirteen of these patients were previously described [31] as “consecutively harvested but not treated”. This analysis now describes, for the first time, comparison of survival through up to 3 years of both study groups (Vigil™ treated and non-Vigil™ treated).

## **STATISTICAL ANALYSIS**

Statistical analyses were performed using IBM SPSS Version 22. Overall survival from time of surgical procurement or from time of treatment was analyzed using Kaplan-Meier curves. Actual 1-year survival difference between treatment groups was determined using the Fisher's Exact Test. All patients were censored alive using the last known date alive.

## **RESULTS**

### **Patient Characterization**

All 30 Ewing's sarcoma patients who signed MCCRC IRB approved consent and qualified for phase 1 testing with Vigil™ were evaluated in this analysis. All had late stage (i.e.,  $\geq$  third line chemotherapy; n=17) or relapse < 2 years of front-line treatment (n=13). One hundred sixty-three vaccine vials were successfully manufactured. Sixteen patients had successful vaccine construction and received Vigil™. Median follow up at the time of reporting was 2 years 11 days. Median time from procurement to first treatment was 53 days. Five treated patients had between 104 and 294 days delay from procurement to treatment. An additional chemotherapy regimen was administered after procurement but prior to Vigil™ treatment in 3 of these 5 patients. Limited field palliative radiation therapy was administered to the other 2 patients with Vigil™ delivery. Three of the 5 remain alive and two passed away 37 days and 430 days after Vigil™ treatment. Fourteen patients in the comparative group did not receive Vigil™ after undergoing similar surgery and vaccine construction process. Nine of the latter were unable to have vaccine released (6 contaminant, 3 insufficient viable tumor cells) and 5 chose other treatment management. One patient in the No Vigil™ group had progression and mortality



before reaching the median time for vaccination in the treatment group. This patient fulfilled the same inclusion criteria as all other patients at time of procurement for surgical justification and study engagement. All vaccines constructed fulfilled release criteria of GMCSF production (1 exception with insufficient material for GMCSF testing) and TGF  $\beta$  1,  $\beta$  2 knockdown.

Demographics of patients entered in the long-term follow up analysis are shown in **Table 1**.

Though not statistically significant, there was a higher ratio of male patients in the Vigil™ arm.

## **Safety**

No significant toxicity was observed in the 16 Vigil™ treated patients. Specifically no product related Grade 3, 4 toxic effects were demonstrated during the treatment course or in long-term follow-up. Ninety-three injections of Vigil™ have been administered to the 16 patients. Adverse Events (AE's) reported are shown in **Table 2**.

There were 11 serious adverse events (SAE's) reported involving 7 participants (See **Table 3**).

None of the SAE's were related to Vigil™. Seventeen deaths (7 Vigil™, 10 No-Vigil™) have occurred, none of which were determined to be related to Vigil™.

## **Response**

Figure 2 shows the results of the Kaplan-Meier analysis of the survival data. Overall survival from time of procurement revealed a 17.2 month improvement in survival in the Vigil™ treated

patients compared to the No Vigil™ group. The median survival for the Vigil™-treated group from time of treatment was 22.7 months (689 days).

The actual 1-year survival of patients who received Vigil™ (11/15, 73%) was higher than those who did not receive Vigil™ (3/13, 23%) (one in each of the Vigil™ and No Vigil™ have not yet achieved the 1-year survival time point).

One patient was previously reported as achieving partial response as per RECIST 1.1 criteria (at 2.7 months after immunotherapy initiation the sum of target lung tumor diameters had decreased from 9.3 cm to 5.3 cm; a 46% decrease) (#089). He progressed 20.6 months after procurement (17.9 months after treatment initiation). Six of the other 15 patients maintained stable disease  $\geq 3$  months. Another patient (#062), who demonstrated recurrent disease 20.4 months (622 days) after prolonged stable disease, underwent a second harvest to procure tumor for treatment for recurrent disease as previously described [31]. She received no further systemic therapy since second treatment with Vigil™ harvested from recurrent disease and now no longer demonstrates evidence of Ewing's sarcoma by imaging 42.4 months (1291 days) after initial procurement.

## **DISCUSSION**

The majority of relapsed Ewing's sarcoma patients who do not achieve a second remission, as well as those who go into a second remission but subsequently relapse, do not derive significant benefit from additional chemotherapy. Previously published results of 161 patients treated with second-line chemotherapy, comparing non-responding patients (SD/PD) to responding patients

(PR/CR) revealed a 5-year survival of 4% vs. 25% (2-year survival 10% versus 45%) [15].

Likewise, response versus no response to second-line chemotherapy was a significant ( $p=.0001$ ) prognostic factor (5-year survival 48% versus 0% respectively) in another series of 55 patients [11]. In a third analysis of 195 patients, 86% of the patients did not achieve second remission; 97% of these patients died with a median survival of 11.7 months and no patient achieved disease control. Of the 26 patients who did go into a second remission, 12 relapsed again and did not reach a third remission (10/12 died and in the first year and 2 were living with uncontrolled disease at 6 and 13 months) [13]. Several targeted and/or targeted plus chemotherapy combination studies are under early clinical or preclinical development (i.e. inhibition of insulin-like growth factor receptor I, midostaurin, YK-4-279, bevacizumab/topotecan/cyclophosphamide, olaparib, enzastaurin, zoledronic acid/ifosfamide) but none have thus far shown significant benefit [30]. **As such, there is a need for treatment development in patients with metastatic Ewing's sarcoma that is refractory to systemic therapy or has progressed after second-line treatment.**

That the “No Vigil™” subset of patients followed was not a prospectively randomized group precludes ascribing significance to interpretation of results. However, insofar as all of these patients traveled to the treatment site, met all inclusion criteria, exhibited none of the exclusion criteria and underwent similar surgical harvest of tumor tissue for Vigil™ construction, we submit that comparison is justifiable albeit with interpretation of results as hypothesis-engendering at best. As shown in results, the demographics of the No Vigil™ versus Vigil™ groups appear well-balanced viv-a-vis prognostic factors that might be expected to affect survival based on historical data.

Regarding evaluation of the comparative findings; the results in the published literature that consistently reflect the severely limited survival of this population of Ewing's sarcoma patients do not necessarily apply to the selected subset of patients in the current report who, in addition to performance status, are also surgical candidates (particularly so for thoracic surgery that was performed in most of the Vigil™/No Vigil™ patients). Thus, despite a perceived survival advantage of Vigil™ treated patients when compared to historical study patients who received alternative systemic therapies, there could be an unintended bias towards a healthier patient population that could have produced skewed results. However, the comparison to the concurrently accrued "No Vigil™" population would strongly suggest that the reported survival prolongation is indeed meaningful. In addition, these results are also consistent with the data previously presented from the Phase 1 study in which a prolongation in median survival was also shown in adult cancer patients treated with Vigil™ [32, 33].

Given these results of Vigil™ in advanced Ewing's sarcoma, our study group consensus under FDA IND support is that a randomized assessment of Vigil™ in this population is justified. To that end, a randomized, controlled, open label Phase 2 study of Vigil™ vs. systemic chemotherapy in  $\geq$  third-line treatment of patients with metastatic Ewing's sarcoma is now underway (NCT02511132).

## ACKNOWLEDGEMENTS

We gratefully acknowledge the generous support of the Helen L. Kay Charitable Trust, the Jasper L. and Jack Denton Wilson Foundation, The Marilyn Augur Family Foundation, Michele Ashby, the Rutledge Foundation, the Speedway Children's Charities, Triumph Over Kid Cancer Foundation, Wipe Out Kids' Cancer, and the family and friends of Sam Day. The authors would like to acknowledge Michelle Watkins and Brenda Marr for their competent and knowledgeable assistance in the preparation of the manuscript. We also thank Lee Helman MD and Mark Thornton MD for critical review and comments regarding the database involved in this manuscript.

## Disclosure/Conflict of Interest

The following authors are shareholders in Gradalis, Inc. and Strike Bio: Gladice Wallraven, Sam Whiting, Donald Rao, Neil Senzer and John Nemunaitis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

## REFERENCES

1. Esiashvili, N., M. Goodman, and R.B. Marcus, Jr., *Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data*. J Pediatr Hematol Oncol, 2008. **30**(6): p. 425-30.
2. 2015 revised 11/19/2015 12/13/15]; Available from: <http://www.cancer.gov/types/bone/hp/ewing-treatment-pdq>.
3. Cotterill, S.J., et al., *Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group*. J Clin Oncol, 2000. **18**(17): p. 3108-14.
4. Stahl, M., et al., *Risk of recurrence and survival after relapse in patients with Ewing sarcoma*. Pediatr Blood Cancer, 2011. **57**(4): p. 549-53.
5. Ozaki, T., et al., *Significance of surgical margin on the prognosis of patients with Ewing's sarcoma. A report from the Cooperative Ewing's Sarcoma Study*. Cancer, 1996. **78**(4): p. 892-900.
6. Bacci, G., et al., *Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies*. Cancer, 1998. **82**(6): p. 1174-83.
7. Klingebiel, T., et al., *Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial*. Med Pediatr Oncol, 1998. **30**(5): p. 269-75.
8. Leavey, P.J. and A.B. Collier, *Ewing sarcoma: prognostic criteria, outcomes and future treatment*. Expert Rev Anticancer Ther, 2008. **8**(4): p. 617-24.
9. Rodriguez-Galindo, C., et al., *Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999*. Cancer, 2002. **94**(2): p. 561-9.
10. Shankar, A.G., et al., *Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma*. Med Pediatr Oncol, 2003. **40**(3): p. 141-7.
11. Barker, L.M., et al., *Survival after recurrence of Ewing's sarcoma family of tumors*. J Clin Oncol, 2005. **23**(19): p. 4354-62.
12. McTiernan, A.M., et al., *Improving Outcomes After Relapse in Ewing's Sarcoma: Analysis of 114 Patients From a Single Institution*. Sarcoma, 2006. **2006**: p. 83548.
13. Bacci, G., et al., *Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997*. Ann Oncol, 2003. **14**(11): p. 1654-9.
14. Hamilton, S.N., et al., *Long-term Outcomes and Complications in Pediatric Ewing Sarcoma*. Am J Clin Oncol, 2015.
15. Rasper, M., et al., *The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma*. Pediatr Blood Cancer, 2014. **61**(8): p. 1382-6.
16. Navid, F., et al., *Second cancers in patients with the Ewing sarcoma family of tumours*. Eur J Cancer, 2008. **44**(7): p. 983-91.
17. Merchant, T.E., et al., *Effect of low-dose radiation therapy when combined with surgical resection for Ewing sarcoma*. Med Pediatr Oncol, 1999. **33**(2): p. 65-70.
18. Saylor, R.L., 3rd, et al., *Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study*. J Clin Oncol, 2001. **19**(15): p. 3463-9.
19. Wagner, L.M., et al., *Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma*. Pediatr Blood Cancer, 2007. **48**(2): p. 132-9.

20. Wagner, L.M., et al., *Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors*. Clin Cancer Res, 2004. **10**(3): p. 840-8.
21. Wagner, L.M., et al., *Oral irinotecan for treatment of pediatric solid tumors: ready for prime time?* Pediatr Blood Cancer, 2010. **54**(5): p. 661-2.
22. Wagner, L.M., et al., *Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study*. Pediatr Blood Cancer, 2010. **54**(4): p. 538-45.
23. Wagner, L., et al., *Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors*. Pediatr Blood Cancer, 2013. **60**(9): p. 1447-51.
24. Casey, D.A., et al., *Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience*. Pediatr Blood Cancer, 2009. **53**(6): p. 1029-34.
25. Raciborska, A., et al., *Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma*. Pediatr Blood Cancer, 2013. **60**(10): p. 1621-5.
26. McGregor, L.M., et al., *Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors*. Pediatr Blood Cancer, 2011. **58**(3): p. 372-9.
27. Navid, F., et al., *Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma*. Cancer, 2008. **113**(2): p. 419-25.
28. Mora, J., et al., *Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel*. J Pediatr Hematol Oncol, 2009. **31**(10): p. 723-9.
29. Rapkin, L., et al., *Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas*. Pediatr Blood Cancer, 2012. **59**(5): p. 854-8.
30. Gaspar, N., et al., *Ewing Sarcoma: Current Management and Future Approaches Through Collaboration*. J Clin Oncol, 2015. **33**(27): p. 3036-46.
31. Ghisoli, M., et al., *Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma*. Mol Ther, 2015. **23**(6): p. 1103-9.
32. Senzer, N., et al., *Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer*. Mol Ther, 2012. **20**(3): p. 679-86.
33. Senzer, N., et al., *Long Term Follow Up: Phase I Trial of "bi-shRNA furin/GMCSF DNA/Autologous Tumor Cell" Immunotherapy (FANG™) in Advanced Cancer* Journal of Vaccines and Vaccination, 2013. **4**(8): p. 209.

**FIGURE LEGEND**


**Figure 1.** A) Vigil™ is a 5140bp plasmid of a bi-functional shRNA-furin DNA sequence which prevents cleavage of TGFβ precursor into functional TGFβ<sub>1</sub> & TGFβ<sub>2</sub> and a GMCSF DNA sequence which stimulates antigen presentation and adaptive immune response when expressed after placement by electroporation into individual autologous tumor tissue which provides the full tumor antigen (Ag) profile and has demonstrated in Phase I, II testing induction of circulating cytotoxic T lymphocytes (CTL) capable of specific lytic activity (ELISPOT and response) to autologous tumor. B) Vigil™ constructing is portrayed.

**Figure 2.** Survival from surgical procurement of advanced Ewing's patients successfully harvested for Vigil™ construction (n=30). Comparison is made of those who received Vigil™ (n=16) vs. those who did not receive Vigil™ ((n=14) as a result of construction failure or choice of other management). All patients are censored alive as of dates provided on 10/19/15.




Figure 1

A




**B**

4 Vigil is thawed and delivered intradermally



**Figure 2**



**No. at Risk**

Vigil	16	14	12	11	11	8	5	4	3	1	1	1	1
No Vigil	14	11	9	6	3	2	2	1	1	1	1	0*	0*

\*Subject lost to follow-up.

Group	N	No. of Deaths	Mean Survival (months)	Median Survival (months)	p-value (Log Rank)
No Vigil™	14	10	13.4 (409 days)	6.8 (207 days)	.056
Vigil™	16*	7	23.1 (704 days)	24 (731 days)	

**Table 1.** Ewing's Sarcoma Phase I Demographics

	<b>Vigil™</b>	<b>No Vigil™*</b>
Tumor Location Harvest (Lung/Soft Tissue/Other)	13/0/3	11/2/1
Sex (M/F)	12/4	7/7
Age median (range)	19 (59-12)	17 (30-12)
Performance (ECOG 0, 1)	16	14
Ethnicity (Caucasian/Other)	13/3	12/2
Prior Systemic Tx (Frontline/2nd/≥3rd)	1/5/10	3/4/7
Surgical Candidate (Yes/No)	16/0	14/0
Tissue Harvested (Yes/No)	16/0	14/0
Median Time Consent to Surgery	1 day	1 day
Metastatic Disease (Yes/No)	16/0	14/0
* 3 insufficient viable tumor cells, 6 contaminants, 5 sought other management		

**Table 2.** Ewing's Sarcoma patients who received Vigil™, definitely or probably related adverse events and long term follow up

<b>Preferred Term</b>	<b>CTC Grade</b>	<b>Relationship to Study Drug</b>	<b>Number of Subjects</b>	<b>Number of Events</b>
Bruising	1	Definitely Related	1	1
Erythema @ Injection Site	1	Definitely Related	1	1
Fatigue	1	Probably Related	1	4
Induration / Fibrosis Injection Site Reaction- Induration	1	Definitely Related	2	2
Injection Site Reaction - Induration	1	Definitely Related	1	2
Injection Site Reaction- Erythema	1	Definitely Related	11	31
Injection Site Reaction- Induration	1	Definitely Related	12	55
Injection Site Reaction- Pain	1	Definitely Related	3	3
Injection Site Reaction- Pruritus	1	Definitely Related	1	3
Injection Site Reaction- Swelling	1	Definitely Related	2	3
Injection Site Reaction- Tenderness	1	Definitely Related	1	1
Joint-function	1	Probably Related	1	2
Pain – Back	1	Probably Related	1	1

**Table 3.** Phase I Ewing's Sarcoma: Serious Adverse Events Reported and long term follow up

ID#	Last Dose Date prior to AE	Onset Date	Resolved Date	Reported Term	Grade	Date of Death	Drug Related Assessment
058	10/01/12	10/16/12	10/19/12	Left Hip Pain	3	10/29/12	Unrelated
058	10/01/12	10/25/12	10/29/12	Disease Progression of Ewing's Sarcoma	5	10/29/12	Unrelated
063	03/12/13	03/19/13	03/26/13	Pain (Bone)	3	04/17/13	Unrelated
063	03/12/13	03/19/13	03/26/13	Constipation	3	04/17/13	Unrelated
092	02/03/15	02/16/15	03/06/15	Possible Infection	2	N/A	Unrelated
102	01/12/15	02/09/15	02/10/15	Malignant Neoplasm, Right Upper Lobe of Lung	2	N/A	Unrelated
104	08/08/14	08/27/14	08/29/14	Intractable Cancer Pain	3	N/A	Unrelated
107	09/12/14	09/16/14	09/25/14	Intractable pain right posterolateral chest	3	09/25/14	Unrelated
107	09/12/14	09/16/14	09/25/14	Disease Progression of Ewing's Sarcoma	5	09/25/14	Unrelated
121	05/15/15	06/02/15	06/03/15	Pneumonia	2	06/28/15	Unrelated
121	06/12/15	06/28/15	06/28/15	Disease Progression of Ewing's Sarcoma	5	06/28/15	Unrelated